



JC02 Rec'd PCT/PT 22 AUG 2005

CT #3

PATENT  
4614-0160PUS1

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: DONATH, Marc Conf.: 5584  
Appl. No.: 10/517,450 Group:  
Filed: December 9, 2004 Examiner:  
For: USE OF AN INTERLEUKIN 1 RECEPTOR  
ANTAGONIST AND/OR  
PYRROLIDINEDITHIOCARBAMATE FOR THE  
TREATMENT OR PROPHYLAXIS OF TYPE 2  
DIABETES

INFORMATION DISCLOSURE STATEMENT  
(SUBMISSION AFTER FILING OF AN APPLICATION  
BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE  
OR CONCURRENTLY WITH A RULE 1.114 RCE APPLICATION)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

August 18, 2005

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449(s), attached hereto.

II. COPIES (check at least one box)

- a. ☒ Copies of cited U.S. patents and patent application publications are not included. Copies of foreign patent documents and non-patent literature are included.
- b. ☐ Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

III. CONCISE EXPLANATION OF THE RELEVANCE  
(check at least one box)

a. ☒ **DOCUMENTS IN THE ENGLISH LANGUAGE**

The patents, publications, or other information listed on the attached PTO 1449 are in the English language and therefore, do not require a statement of relevancy.

b. ☐ **DOCUMENTS NOT IN THE ENGLISH LANGUAGE**

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. ☐ **ENGLISH LANGUAGE SEARCH REPORT**

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).

d. ☐ **OTHER**

The following additional information is provided for the Examiner's consideration.

FEEES

IV. ☒ THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b):  
(check one box)

- a. ☐ within three months of the filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required. *(This section is not to be used with RCE's.)*
- b. ☐ within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required.
- c. ☐ concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.
- d. ☒ before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required.  
In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).

V. ☐ THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):  
(check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).

- a. ☐ No statement; therefore, a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).
- or
- b. ☐ See the statement below. No fee is required.

VI. STATEMENT UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby states that

- a. ☐ each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this IDS; or
- b. ☐ each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- c. ☐ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS.
- d. ☐ Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

VII. PAYMENT OF FEES (check one box)


- ☐ A check in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p) is enclosed for the above-identified fee.
- ☐ Please charge Deposit Account No. 02-2448 in the amount required by 37 C.F.R. § 1.17(p) for the above-indicated fee. This paper is submitted in triplicate.
- ☒ No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By   
Leonard R. Svensson, #30,330


LRS/lmt  
4614-0160PUS1

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000


- Attachment(s): ☒ PTO-1449  
☒ Documents  
☐ Foreign Search Report  
☐ Fee  
☐ Other:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on: August 18, 2005  
(Date of Deposit)


BIRCH, STEWART, KOLASCH & BIRCH, LLP

  
(Signature)  
August 18, 2005  
(Date of Signature)

Form PTO-1449		ATTY. DOCKET NO. 4614-0160PUS1		APPLICATION NO. 10/517,450					
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> (Use several sheets if necessary)		APPLICANT DONATH, Marc							
		FILING DATE December 9, 2004		GROUP					
<b>U.S. PATENT DOCUMENTS</b>									
EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
	US								
<b>FOREIGN PATENT DOCUMENTS</b>									
	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
	EP	1018514A1		7/00	EPO			YES	NO
<b>OTHER DOCUMENTS</b> (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.									
	Blocking IL-1: Interleukin 1 receptor antagonist in vivo and in vitro, Charles A. Dinarello, et al., <i>Immunology Today</i> , Vol. 12 No. 11 199, pp. 404-410								
	Involvement of Interleukin 1 and Interleukin 1 Antagonist in Pancreatic B-Cell Destruction in Insulin-Dependent Diabetes Mellitus, Thomas Mandrup-Poulson, et al., <i>Cytokine</i> , Vol. 5, No. 3 (May), 1993 pp. 185-191								
	IL-1 Receptor Antagonist Serum Levels Are Increased in Human Obesity: A Possible Link to the Resistance to Leptin?, Christoph A. Meier, et al., <i>The Journal of Clinical Endocrinology &amp; Metabolism</i> 87(3):1184-1188								
	Hyperglucemia-Induced B-Cell Apoptosis in Pancreatic Islets of Psammomys obesus During Development of Diabetes, Marc Y. Donath, et al., <i>Diabetes</i> , Vol. 48 April 1999, 738-744								
	Pyrrolidine Dithiocarbamate Prevents IL-1-Induced Nitric Oxide Synthase mRNA, but not Superoxide Dismutase mRNA, in Insulin Producing Cells, F.J. Bedoyua, et al., <i>Biochemical and Biophysical Research Communications</i> , Vol. 210, No.3 1995, pp.816-822								
	Role of the NF-kB Pathway in the Pathogenesis of Human Disease States, Yumi Yamamoto and Richard Gaynor, <i>Current Molecular Medicine</i> 2001, 1, pp. 287-296								
	Cyokines Activate the Nuclear Factor kB (NF-kB) and Induce Nitric Oxide Production in Human Pancreatic Islets, Maline Flodström, et al., <i>Federation of European Biochemical Societies</i> 285 (1996) 4-6								
	Glucose-induced B cell Production of IL-1B contributes to Glucotoxicity in Human Pancreatic Islets, Kathrin Maedler, et al., <i>The Journal of Clinical Investigation</i> , Sept. 2002, Vol. 110, Number 6, pp. 851-860								
	Hyperglycaemia as an Inducer as well as a Consequence of Impaired Islet Cell Function and Insulin Resistance: Implications for the Management of Diabetes, R.H. Under, et al., <i>Diabetologia</i> , (1985) 28: 119-121								
	Monolayer Culture of Adult Rat Pancreatic Islets on Extracellular Matrix: Modulation of B-Cell Function by Chronic Exposure to High Glucose, Nurit Kaiser, et al., <i>Endocrinology</i> , Vol. 129, No. 4, pp. 2067-2075								
	Chronic Hyperglycemia Is Associated with Impaired Glucose Influence on Insulin Secretion, A Study in Normal Rats Using Chronic In Vivo Glucose Infusions, L. J. Leahy, et al., <i>J. Clinical Invest.</i> , Vol. 77 March 1986, pp. 908-915								
	Perspective in Diabetes, Type II Diabetes, Glucose "Non-Sense," and Islet Desensitization, R. Paul Robertson, <i>Diabetes</i> , Vol. 38, December 1989, pp. 1501-1505								
	Glucose Toxicity, Luciano Rossetti, M.D., et al., <i>Diabetes Care</i> , Vol 13, No. 6, June 1990, pp. 610-630								
EXAMINER					DATE CONSIDERED				



	Prolonged Exposure of Human Pancreatic Islets to High Glucose Concentrations in Vitro Impairs the B-Cell Function, Decio L. Elizirik, et al., <i>J. Clin. Invest.</i> , Vol. 90, October 1992, pp. 1263-1268
	Impaired B-Cell Functions Induced by Chronic Exposure of Cultured Human Pancreatic Islets to High Glucose, Sonya Marchak, et al., <i>Diabetes</i> , Vol. 48m June 1999, pp. 1230-1236
	Glucose Induces B-Cell Apoptosis Via Upregulation of The Fas Receptor in Human Islets, Kathrin Maedler, et al., <i>Diabetes</i> , Vol. 50, August 2001, pp. 1683-1690
	High Glucose Causes Apoptosis in Cultured Human Pancreatic Islets of Langerhans, A Potential Role for Regulation of Specific Bcl Family Genes Toward an Apoptotic Cell Death Program, Massimo Federici, et al., <i>Diabetes</i> , Vol. 50, June 2001, pp. 1290-1301
	Glucose and Tolbutamide Induce Apoptosis in Pancreatic B-Cells, Ioulia B. Efanova, et al., <i>The Journal of Biological Chemistry</i> , Vol. 273, No. 50, Issue of December 11, pp.33501-33507
	Distinct Effects of Saturated and Monounsaturated Fatty Acids on B-Cell Turnover and Function, K. Maedler, et al., <i>Diabetes</i> , Vol. 50, January 2001, pp. 69-76
	Long Term Effects of Aminoguanidine on Insulin Release and Biosynthesis: Evidence That the Formation of Advanced Glycosylation End Products Inhibits B Cell Function, Yuji Tajiri, et al., <i>Endocrinology</i> , Vol. 138, No. 1, pp. 273-280
	Preservation of Insulin mRNA Levels and Insulin Secretion in HIT Cells by Avoidance of Chronic Exposures to High Glucose Concentrations, R. Paul Robertson, <i>J. Clin. Invest.</i> , Vol. 90, August 1992, pp. 320-325
	Differentiating Glucose Toxicity From Glucose Desensitization: A New Message From the Insulin Gene, R. Paul Robertson, et al., <i>Diabetes Center and the Division of Diabetes, University of Minnesota Medical School</i>
	The Role of Interleukin-1 in the Pathogenesis of IDDM, T. Mandrup-Poulsen, <i>Diabetologia</i> (1996) 39: pp. 1005-1029
	Cytokines Cause Functional and Structural Damage to Isolated Islets of Langerhans, T. Mandrup-Poulsen, et al., <i>Allergy</i> 1985, 40, pp. 424-429
	Cytotoxicity of Human p1 7 Interleukin-1 for Pancreatic Islets of Langerhans, Klaus Bendtzen, et al., <i>Science</i> , Vol. 232, pp. 1545-1547
	Interleukin 1 Dose-Dependently Affects the Biosynthesis of (pro) Insulin in Isolated Rat Islets of Langerhans, G.A Spinas, et al., <i>Diabetologia</i> , (1987) 30: pp. 474-480
	Affinity-Purified Human Interleukin I is Cytotoxic to Isolated Islets of Langerhans, T. Mandrup-Poulsen, <i>Diabetologia</i> , (1987) 29: pp. 63-67
	Low Concentrations of Interleukin - 1 Stimulate and High Concentrations Inhibit Insulin Release from Isolated Rat Islets of Langerhans, Giatgen A. Spinas, et al., <i>ACTA Endocrinologia (Copenh)</i> (1986), 113: pp.551-558
	Mouse Islet Cell Lysis Mediated by Interleukin-1-Induced Fas, K. Yamada, et al., <i>Diabetologia</i> (1996) 39: pp.1306-1312
	Interleukin-1B-Induced Formation of EPR-Detectable Iron-Nitrosyl Complexes in Islets of Langerhans, John A. Corbett, et al., <i>The Journal of Biological Chemistry</i> , Vol. 266, No. 32, pp. 21351-21354
	Adenoviral Gene Transfer of the Interleukin-1 Receptor Antagonist Protein To Human Islets Prevents IL-1B-Induced B-Cell Impairment and Activation of Islet Cell Apoptosis In Vitro, Nich Giannoukakis, et al., <i>Diabetes</i> , Vol. 48, September 1999, pp. 1730-1736
	Prevention of Beta Cell Dysfunction and Apoptosis Activation in Human Islets by Adenoviral Gene Transfer of the Insulin-Like Growth Factor, N. Giannoukakis, et al, <i>Gene Therapy</i> (2000) 7, pp.2015-2022
	Human Islets of Langerhans Express Fas Ligand and Undergo Apoptosis in Response to Interleukin-1B and Fas Ligation, Anne C. Loweth, et al., <i>Diabetes</i> , Vol. 47, May 1998, pp. 727-732
	Cytotoxic Effects of Cytokines on Human Pancreatic Islet Cells in Monolayer Culture, Alexander Rabinovitch, et al., <i>Journal of Clinical Endocrinology and Metabolism</i> , Vol. 71, No. 1, pp.152-156
EXAMINER	DATE CONSIDERED



	Nitric Oxide Primes Pancreatic B Cells for Fas-Mediated Destruction in Insulin-Dependant Diabetes Mellitus, Giorgio Stassi, et al., <i>J. Exp. Med.</i> , Vol. 186, Number 8, October 20, 1997, pp.1193-1200
	Interleukin-1B-Induced Nitric Oxide Synthase Expression by Rat Pancreatic B-Cells: Evidence for the Involvement of Nuclear Factor kB in the Signaling Mechanism, Guim Kwon, et al., <i>Endocrinology</i> , Vol. 136, No. 11, pp. 4790-4795
	Cytokine Induction of Fas Gene Expression in Insulin-Producing Cells Requires the Transcription Factors NF-kB and C/EBP, Martine I. Darville, et al., <i>Diabetes</i> , Vol. 50, pp 1741-1748
	Cytokines Activate the Nuclear Factor kB (NF-kB) and Induce Nitric Oxide Production in Human Pancreatic Islets, Malin Flodström, et al., <i>Federation of European Biochemical Societies</i> , 385, (1996) pp.4-6
	Improved Human Islet Isolation Using a New Enzyme Blend, Liberase, Elina Linetsky, et al., <i>Diabetes</i> , Vol. 46, July 1997, pp. 1120-1123
	Human Islet Transplantation, José Oberholzer, et al., <i>Transplantation</i> , Vol. 69, No. 6, March 27, 2000, pp. 1115-1123
	Automated Method for Isolation of Human Pancreatic Islets, Camillo Ricordi, et al., <i>Diabetes</i> , Vol. 37, April 1988, pp. 413-420
	Monolayer Culture of Adult Rat Pancreatic Islets on Extracellular Matrix: Modulation of B-Cell Function by Chronic Exposure to High Glucose, Nurit Kaiser, et al., <i>Endocrinology</i> , Vol. 129, No. 4, pp. 2067-2076
	Apoptosis-Inducing Membrane Vesicles, Satoshi Jodo, et al., <i>The Journal of Biological Chemistry</i> , Vol. 276, No. 43, Issue of October 26, 2001, pp. 39938-39944
	Nitric Oxide Synthase Is Not a Constituent of the Antimicrobial Armature of Human Mononuclear Phagocytes, Markus Schneemann, et al., <i>The Journal of Infectious Diseases</i> , 1993, 167, pp. 1358-1363
	Identification of Programmed Cell Death In Situ via Specific Labeling of Nuclear DNA Fragmentation, Yael Gavrieli, et al., <i>The Journal of Cell Biology</i> , Vol. 119, Number 3, November 1992 pp. 493-501
	N-Terminal DNA-Binding Domains Contribute to Differential DNA-Binding Specificities of NF-kB p50 and p65, Michel B. Toledano, et al., <i>Molecular and Cellular Biology</i> , Feb. 1993, Vol. 13, No. 2, pp. 852-860
	How NF-kB is Activated: The Role of the Ikb Kinase (IKK) Complex, Michael Karin, <i>Oncogene</i> , (1999) 18; pp.6867-6874
	B-Cell Death During Progression to Diabetes, Diane Mathis, et al., <i>Nature</i> , Vol 414, Dec. 2001 pp. 792-798
	Evidence of Islet Cell Autoimmunity in Elderly Patients with Type 2 Diabetes, Massimo Pietro, et al., <i>Diabetes</i> , Vol. 49, Jan. 2000, pp. 32-38
	Antibodies to Glutamic Acid Decarboxylase Discriminate Major Types of Diabetes Mellitus, Merrill J. Rowley, et al., <i>Diabetes</i> , Vol. 41, April 1992, pp. 548-551
	The Accelerator Hypothesis: Weight Gain as the Missing Link Between Type I and Type II Diabetes, T. J. Wilkin, <i>Diabetologia</i> (2001) 44:pp 914-922
	Processing of Engulfed Apoptotic Bodies Yields T Cell Epitopes, Matteo Bellone, et al., <i>The Journal of Immunology</i> 1997, 159:pp. 5391-5399
	Perspectives in Diabetes Neonatal B-Cell Apoptosis, A Trigger for Autoimmune Diabetes?, Jacqueline D. Trudeau, et al., <i>Diabetes</i> , Vol. 49, January 2000 pp.1-7
	Activation of Intra-islet Lymphoid Cells Causes Destruction of Islet Cells, Paul E. Lacy, et al., <i>American Journal of Pathology</i> , Vol. 138, No. 5, May 1991, pp. 1183-1190
	The Intra-islet Macrophage and Type I Diabetes, Paul E. Lacy M.D., <i>The Mount Sinai Journal of Medicine</i> , Vol. 61, No. 2, March 1994, pp. 170-174
	Potential Role of Resident Islet Macrophage Activation in the Initiation of Autoimmune Diabetes, Marc Arnush, et al., <i>The Journal of Immunology</i> , 1998, 160: pp.2684-2691
	Pancreatic B-Cell Damage Mediated by B-Cell Production of Interleukin-1, Monique R. Heitmeier, et al., <i>The Journal of Biological Chemistry</i> , Vol. 276, No. 14, April 6, 2001, pp. 11151-11158



AUG 22 2005

Sheet 4 of 5 (08/18/05)

	Hyperproinsulinemia and Insulin Deficiency in the Diabetic Psammomys obesus, M. Salot, et al., <i>Endocrinology</i> , May 20, 2005, Vol. 135, No. 10, pp. 3325-3332
	Monocyte Chemoattractant Protein-1 is Expressed in Pancreatic Islets from Prediabetic NOD Mice and In Interleukin-1B-exposed Human and Rat Islet Cells, M.-C Chen, et al., <i>Diabetologia</i> (2001) 44: pp. 325-332
	B-Cell Apoptosis and Defense Mechanisms, Lessons from Type 1 Diabetes, Decio L. Elizirik, et al., <i>Diabetes</i> , Vol. 50, Suppl. 1, Feb. 2001, pp. S64-S69
	Cytokines Induce Apoptosis in B-Cells Isolated From Mice Lacking the Inducible Isoform of Nitric Oxide Synthase (iNOS-/-), Dongbo Liu, et al., <i>Diabetes</i> , Vol. 49, July 2000, pp. 1116-2000
	Nitric Oxide Production and Fas Surface Expression Mediate Two Independent Pathways of Cytokine-Induced Murine B-Cell Damage, Urs Zumsteg, et al., <i>Diabetes</i> , Vol. 49, Jan. 2000, pp. 39-47
	Protection of Human Islets from the Effects of Interleukin-1B by Adenoviral Gene Transfer of an Ikb Repressor, Nich Giannoukakis, et al., <i>The Journal of Biological Chemistry</i> , Vol. 275, No. 47, Issue of Nov. 24, 2000, pp. 36509-36513
	Nitric Oxide Mediates Cytokine-Induced Inhibition of Insulin Secretion by Human Islets of Langerhans, John A. Corbett, et al., <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 90 pp. 1731-1735, March 1993 <i>Medical Sciences</i>
	Hyperglycemia-Induced Activation of Nuclear Transcription Factor kb in Vascular Smooth Muscle Cells, Kiran Kumar, et al., <i>Diabetes</i> , Vol. 48, April 1999, pp. 855-864
	Inhibition of Cytokine-Induced NF-kB Activation by Adenovirus-Mediated Expression of a NF-kB Super-Repressor Prevents B-Cell Apoptosis, Harry Heimberg, et al., <i>Diabetes</i> , Vol. 50, Oct. 2001, pp. 2219-2224
	Imidazoline Compounds Protect Against Interleukin 1B-Induced B-Cell Apoptosis, Sergei V. Zaitsev, et al., <i>Diabetes</i> , Vol. 50, Suppl. 1, Feb. 2001, pp. S70-S76
	Improved Beta-Cell Function after Intensive Insulin Treatment in Severe Non-Insulin-Dependent Diabetes, Benjamin Glaser, et al., <i>ACTA Endocrinologica, (Copenh)</i> 1988, 118: pp. 365-373
	B-Cell Deficit and Increased B-Cell Apoptosis in Humans With Type 2 Diabetes, Alexandra E. Butler, et al., <i>Diabetes</i> , Vol. 52, January 2003, pp. 102-110
	Early Differential Defects of Insulin Secretion and Action in 19-Year-Old Caucasian Men Who Had Low Birth Weight, Christine B. Jensen, et al., <i>Diabetes</i> , Vol. 51, April 2002, pp. 1271-1280
	Age-Dependent Impact of Zygosity and Birth Weight on Insulin Secretion and Insulin Action in Twins, P. Poulsen, et al., <i>Diabetologia</i> (2002), pp. 1649-1657
	Metabolic Impact of a Family History of Type 2 Diabetes. Results from a European Multicentre Study (EGIR), A. Vaag, et al., 2001 <i>Diabetes UK. Diabetic Medicine</i> , 18, pp. 553-540
	Journal Symposium, Islet Growth and Development in the Adult, S. Bonner-Weir, <i>Journal of Molecular Endocrinology</i> (2000) 24, pp.297-302
	Islet Pathology and the Pathogenesis of Type 1 and Type 2 Diabetes Mellitus Revisited, Günter Klöppel, et al., <i>Surv. Synth. Path. Res.</i> 4: pp. 110-125 (1985)
	Reduced Beta-Cell Mass and Expression of Oxidative Stress-Related DNA Damage in the Islet of Japanese Type II Diabetic Patients, H. Sakuraba, et al., <i>Diabetologia</i> (2002) 45: pp. 85-96
	Selective B-Cell Loss and z-Cell Expansion in Patients with Type 2 Diabetes Mellitus in Korea, Kun Ho Yoon, et al., <i>The Journal of Clinical Endocrinology &amp; Metabolism</i> 88(5), pp. 2300-2308
	B-Cell Dysfunction and Insulin Resistance in Type 2 Diabetes: Role of Metabolic and Genetic Abnormalities, Derek LeRoith, M.D., Ph.D., FACP, <i>The American Journal of Medicine</i> , Vol. 113(6A), pp. 3S-11S
	Fatty Acids, Lipotoxicity and Insulin Secretion, J.D. McGarry, et al., <i>Diabetologia</i> (1999) 42: pp. 128-138
	The Glucose Fatty Acid Cycle in Obesity and Maturity Onset Diabetes Mellitus, P. J. Randle, et al., <i>Annals New York Academy of Sciences</i> , pp. 324-333
	Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM, Genetic and Clinical Implications, Roger H. Unger, <i>Diabetes</i> , Vol. 44, Aug. 1995, pp. 863-870
EXAMINER	DATE CONSIDERED

AUG 22 2005

Sheet 5 of 5 (08/18/05)

	Monounsaturated Fatty Acids Prevent the Deleterious Effects of Palmitate and High Glucose on Human Pancreatic B-Cell Turnover and Function, Kathrin Maedler, et al., <i>Diabetes</i> , Vol. 52, March 2003, pp. 726-733
	Glucose-Induced B Cell Production of IL-1 $\beta$ Contributes to Glucotoxicity in Human Pancreatic Islets, Kathrin Maedler, et al., <i>The Journal of Clinical Investigation</i> , Sept. 2002, Vol. 110, Number 6, pp. 851-860
	FLIP Switches FAS-Mediated Glucose Signaling in Human Pancreatic B Cells From Apoptosis to Cell Replication, Kathrin Maedler, et al., <i>PNAS</i> , June 11, 2002, Vol. 99, No. 12, pp. 8236-8241
	Islet Secretion in a New Experimental Model for Non-Insulin-Dependent Diabetes, G. C. Weir, et al., <i>Diabetes</i> , Vol. 30, July 1981, pp. 590-595
	Partial Pancreatectomy in the Rat and Subsequent Defect in Glucose-Induced Insulin Release, S. Bonner-Weir, <i>J. Clin. Invest.</i> , Vol. 71, June 1983, pp. 1544-1554
	Hyperglycaemia as an inducer as well as a Consequence of Impaired Islet Cell Function and Insulin Resistance: Implications for the management of diabetes, R. H. Under, et al., <i>Diabetologia</i> (1985) 28: pp. 119-121
	Positional Cloning of the Mouse Obese Gene and its Human Homologue, Yiyang Zhang, et al., <i>Nature</i> , Vol. 372, Dec. 1994, pp. 425-432
	Recombinant Mouse OB Protein: Evidence for a Peripheral Signal Linking Adiposity and Central Neural Networks, L. Arthur Campfield, et al., <i>Science</i> , Vol. 269, July 28, 1995, pp. 546-549
	Expression of the Functional Leptin Receptor mRNA in Pancreatic Islets, Valur Emilsson, et al., <i>Diabetes</i> , Vol. 46, Feb. 1997, pp. 313-316
	Leptin Receptors Expressed on Pancreatic B-Cells, T. Kieffer, et al., <i>Biochemical and Biophysical Research Communications</i> 224, pp. 522-527 (1996), Art. 1059
	Inhibition of Glucose-Induced Insulin Secretion by Long-Term Preexposure of Pancreatic Islets to Leptin, R. Roduit, et al., <i>FEBS Letters</i> 415 (1997) pp. 179-182
	Fetal Pancreatic Islets Express Functional Leptin Receptors and Leptin Stimulates Proliferation of Fetal Islet Cells, MS Islam, et al., <i>International Journal of Obesity</i> (2000) 24, pp. 1246-1253
	Leptin Increases the Viability of Isolated Rat Pancreatic Islets by Suppressing Apoptosis, S. Okuya, et al., <i>Endocrinology</i> , 142, (11) 4827-4830
	Protection Against Lipoapoptosis of B Cells Through Leptin-Dependent Maintenance of Bcl-2 Expression, M. Shimabukuro, et al., <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 95, pp. 9558-9561
	Leptin Induces Proliferation of Pancreatic B Cell Line MIN6 through Activation of Mitogen-Activated Protein Kinase, K. Tanabe, et al., <i>Biochemical and Biophysical Research Communications</i> , 241: pp. 765-768(1997)
	A Urine Inhibitor of Interleukin 1 Activity Affects Both Interleukin 1 $\alpha$ and 1 $\beta$ But Not Tumor Necrosis Factor, P. Seckinger, et al., <i>The Journal of Immunology</i> , Vol. 139, 1541-1545, No. 5, Sept. 1, 1987
	A Urine Inhibitor of Interleukin 1 Activity That Blocks Ligand Binding, P. Seckinger, et al., <i>The Journal of Immunology</i> , Vol. 139, 1546-1549
	Biological Role of Interleukin 1 Receptor Antagonist Isoforms, W. Arend, et al., <i>Am Rheum Dis</i> 2000;59(suppl 1) i60-i64
	Leptin Directly Induces the Secretion of Interleukin 1 Receptor Antagonist in Human Monocytes, C. Gabay, et al., <i>The Journal of Clinical Endocrinology and Metabolism</i> , Vol. 86, NO.2, pp. 783-791
	Inflammatory Mediators and Islet B-Cell Failure: A Link Between Type 1 and Type 2 Diabetes, M. Donath, et al., <i>J. Mol. Med.</i> (2003) 81: 455-470
	Non-Insulin Dependent Diabetes Mellitus..., K. Polonsky M.D., et al., <i>Seminars in Medicine of the Beth Israel Hospital, Boston</i> , Vol. 334, No. 12, pp. 777-783
EXAMINER	DATE CONSIDERED